HUYA to partner with Changzhou Center for Biotech Development to promote local innovation

18 August 2014

Chinese company HUYA Bioscience has announced a partnership with Changzhou Center for Biotech Development, which will focus on meeting critical global pharma pipeline needs.

HUYA is focused on speeding the development of Chinese-sourced biopharma compounds in worldwide markets, and has established a series of collaborations with universities and research institutes throughout China.

The CZCBD is an institutional unit fully funded and supervised by the Changzhou Science and Technology Bureau, and the first biotech development center under local government supervision. Its goal is to establish a comprehensive biopharma innovation system with which to transform production by more than 800 biotech and pharma companies in Changzhou.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK